-2-dioxolan | 60155-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: -2-dioxolan
• 英文别名: 2-(1,3-Dioxolan-2-yl)-1,3-dioxane
• CAS: 60155-73-9
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: XKYPWIFWSWBNQK-UHFFFAOYSA-N

物化性质

• 沸点：
  217.1±35.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Process for the synthesis of 1,3-dihydro-2H-3-benzazepin-2-one compounds, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
  申请人：Lerestif Jean-Michel

  公开号：US20050227962A1

  公开（公告）日：2005-10-13

  Process for the synthesis of compounds of formula (I): wherein R 1 and R 2 , which may be the same or different, each represent a linear or branched (C 1 -C 8 )alkoxy group or form, together with the carbon atom carrying them, a 1,3-dioxane, 1,3-dioxolane or 1,3-dioxepane ring. Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof.

  合成式(I)化合物的过程：其中R1和R2可以相同或不同，分别表示线性或支链(C1-C8)烷氧基团，或与它们相连的碳原子一起形成1,3-二氧杂环戊烷、1,3-二氧杂环己烷或1,3-二氧杂环庚烷环。应用于伊伐布雷定的合成，以及与药学上可接受的酸形成的加合物和水合物的合成。
• NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1467977A1

  公开（公告）日：2004-10-20
• US7074920B2
  申请人：——

  公开号：US7074920B2

  公开（公告）日：2006-07-11
• [EN] NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.<br/>[FR] NOUVEAUX COMPOSES ANTIBACTERIENS, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES CONTENANT DE TELS COMPOSES
  申请人：REDDYS LAB LTD DR

  公开号：WO2003059894A1

  公开（公告）日：2003-07-24

  The present invention relates to novel triazole compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotamers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them. More particularly, the present invention relates to novel triazoles of the general formula (I) their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotamers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.